Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-043852
Filing Date
2025-03-24
Accepted
2025-03-24 16:16:17
Documents
86
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ocx-20241231.htm   iXBRL 10-K 4377729
2 EX-4.7 ocx-ex4_7.htm EX-4.7 15568
3 EX-19.1 ocx-ex19_1.htm EX-19.1 96429
4 EX-23.1 ocx-ex23_1.htm EX-23.1 3153
5 EX-31.1 ocx-ex31_1.htm EX-31.1 14328
6 EX-31.2 ocx-ex31_2.htm EX-31.2 14267
7 EX-32.1 ocx-ex32_1.htm EX-32.1 10155
  Complete submission text file 0000950170-25-043852.txt   16847914

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ocx-20241231.xsd EX-101.SCH 2067642
88 EXTRACTED XBRL INSTANCE DOCUMENT ocx-20241231_htm.xml XML 3092320
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37648 | Film No.: 25764357
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)